Journal News

JLR: A close-up of nascent HDL formation

Laurel Oldach
Jan. 1, 2019

Oil and water don’t mix. But our aqueous blood is full of hydrophobic lipids — including cholesterol. To travel via the bloodstream, those lipids must hitch a ride on an amphipathic carrier. In a paper in the Journal of Lipid Research, scientists at Boston University report an advance in our mechanistic understanding of how one such carrier forms.

“Lipoproteins are like boats that deliver and remove cargoes of fatty substances to and from our cells,” said David Atkinson, chair of the physiology and biophysics department at Boston University School of Medicine and senior author on the JLR paper.

The subset of those “boats” that carry cholesterol and other lipids to the liver from other parts of the body are called high-density lipoproteins, or HDL, aka “good cholesterol.” HDL can remove cholesterol from distal cells — such as macrophages in the walls of arteries, where cholesterol accumulation can lead to heart attacks — and deliver it to liver cells, a process known as reverse cholesterol transport. The liver disposes of excess cholesterol by converting it into bile acids secreted into the small intestine.

According to Atkinson, a biophysicist, most of what is known about HDL formation comes from experiments that take a cell biological tack. In such studies, he said, “You can see (HDL formation) happening, and you can quantitate what happens, but you don’t understand the driving interactions that cause it to happen.”

HDL is built on a scaffold protein, apolipoprotein A-I. This apoA-I is thought to collect cholesterol and phospholipids from the cell membrane. Atkinson’s team wanted to better understand that process.

Lipoprotein particleA model of a high-density lipoprotein particle shows apolipoprotein A-I in pink, phospholipids in gray and cholesterol in yellow.Wu et al/JBC 2009ApoA-I depends on a lipid transporter protein, ABCA1, that pumps cholesterol from the inner to the outer leaflet of the cell membrane. Because the cholesterol that ABCA1 transfers usually ends up bound to apoA-I, some researchers suspected a physical interaction between apoA-I and ABCA1. Others argued that cholesterol and phospholipids could diffuse passively and bind to apoA-I.

“Even if you demonstrate that apoA-I binds to the cell surface, you don’t actually know that it’s bound to ABCA1. It’s just bound to the cell surface,” Atkinson said. So he asked his team to see if they could “demonstrate that interaction actually happening in the isolated components.”

The team, led by graduate student Minjing Liu and supported by Xiaohu Mei and Haya Herscovitz, used isolated apoA-I and ABCA1 to test for a physical interaction. They were able to show immunoprecipitation of apoA-I with purified ABCA1.

The lab earlier had designed a mutant apoA-I with a little extra wiggle in an already flexible hinge region. For this study, they used the mutant to show that higher flexibility increased apoA-I lipidation, or the formation of nascent HDL. The team has not yet tested whether the extra-flexible mutant binds to ABCA1 better or whether binding of either form of apoA-I activates ABCA1.

But about one thing Atkinson is certain: “It’s the apoA-I/ABCA1 interaction which then enables the nascent HDL particle formation to happen as the membrane components are being transported out by ABCA1.”

Increasing reverse cholesterol transport may be a way to reduce atherosclerosis and heart disease. Atkinson is optimistic about the promise of understanding the physiological processes better.

“Translational research might be in vogue,” he said, “but remember that if you don’t do foundational basic discovery research, you will not have anything to translate.”

Enjoy reading ASBMB Today?

Become a member to receive the print edition monthly and the digital edition weekly.

Learn more
Laurel Oldach

Laurel Oldach is a science writer for the ASBMB.

Related articles

From the journals: JLR
Brian O'Flynn
From the journals: JLR
Brian O'Flynn
From the journals: JLR
Vaishnavi Muralikrishnan
From the journals: JLR
Lisa Learman & Laurel Oldach

Get the latest from ASBMB Today

Enter your email address, and we’ll send you a weekly email with recent articles, interviews and more.

Latest in Science

Science highlights or most popular articles

Is there a mystery in the monkeypox antiviral?
News

Is there a mystery in the monkeypox antiviral?

May 24, 2022

As monkeypox becomes an international concern, interest grows in tecovirimat; this smallpox drug targets a structural protein that helps wrap the virus in a second lipid bilayer.

Researchers investigate self-regulation of an enzyme with critical cellular functions
News

Researchers investigate self-regulation of an enzyme with critical cellular functions

May 24, 2022

They found that one mechanism of CK1 activity, and thus one mechanism of regulation, is the self-phosphorylation of a conserved amino acid residue in its catalytic domain.

What is monkeypox?
Science Communication

What is monkeypox?

May 23, 2022

A microbiologist explains what’s known about this smallpox cousin.

A simple method to determine phase preference of proteins on live cell membranes
Journal News

A simple method to determine phase preference of proteins on live cell membranes

May 22, 2022

“The phase preference of molecules used to be difficult and time-consuming to establish. This new method, detected by chance, provides results in at most 15 minutes on live cells,” Thorsten Wohland said.

Study of Alzheimer’s marker prompts warning about serine supplements
News

Study of Alzheimer’s marker prompts warning about serine supplements

May 20, 2022

They have been advertised to improve memory and cognitive function.

Why is the 100-year-old BCG vaccine so broadly protective in newborns?
News

Why is the 100-year-old BCG vaccine so broadly protective in newborns?

May 19, 2022

Study finds changes in metabolite and lipid profiles, providing clues for designing future vaccines for newborns.